Stockreport

Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome [Yahoo! Finance]

Ultragenyx Pharmaceutical Inc.  (RARE) 
Last ultragenyx pharmaceutical inc. earnings: 2/13 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.ultragenyx.com/investor-relations
PDF The primary endpoint of the study is improvement in cognition assessed by Bayley-4 cognitive raw score, and the key secondary endpoint is the Multi-domain Responder Ind [Read more]